# Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

> **NCT03520686** · PHASE3 · TERMINATED · sponsor: **ImmunityBio, Inc.** · enrollment: 102 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** NAI + Pembrolizumab
- **DRUG:** NAI + Nivolumab + Ipilimumab
- **DRUG:** Pembrolizumab
- **DRUG:** NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
- **DRUG:** Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice)
- **DRUG:** Cisplatin/carboplatin and pemetrexed plus pembrolizumab.
- **DRUG:** Cisplatin/carboplatin and pemetrexed plus atezolizumab.
- **DRUG:** Carboplatin and paclitaxel plus atezolizumab and bevacizumab.
- **DRUG:** Carboplatin and nab-paclitaxel plus atezolizumab.
- **DRUG:** NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel

## Key facts

- **NCT ID:** NCT03520686
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-18
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03520686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03520686, "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03520686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*